Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$147.13 USD
+0.05 (0.03%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $146.97 -0.16 (-0.11%) 7:42 PM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Brokerage Reports
Johnson & Johnson [JNJ]
Reports for Purchase
Showing records 461 - 480 ( 501 total )
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Well positioned to step back on growth trajectory from CY12 onwards......
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of September 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Revitalised Pharma pipeline & aggressive new product launch strategy to drive growth.....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
MODEL STOCK PORTFOLIO -CONSERVATIVE GROWTH
Provider: J.J.B. Hilliard, W.L. Lyons
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Revitalised Pharma pipeline & aggressive new product launch strategy to offset patent expiry related slowdown.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Upgrade To Moderate Outperform : Revitalised Pharma pipeline & aggressive new product launch strategy to offset patent expiry related slowdown...
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Raising our CY11 estimates in view of expected forex benefits
Provider: FIRST GLOBAL
Analyst: THOMAS K